Pfizer's Anacor deal showcases new wave of eczema therapies

NEW YORK (Reuters) - Pfizer Inc's purchase of Anacor Pharmaceuticals Inc heralds an approaching wave of potentially safer and more effective treatments for millions who suffer from eczema, a common skin condition which causes infection-prone rashes that can feel like having poison ivy 24 hours a day.

Source: Reuters: Health - May 17, 2016 Category: Consumer Health News Tags: healthNews Source Type: news